MARKET

MRK

MRK

Merck & Co
NYSE

Real-time Quotes | Nasdaq Last Sale

78.41
+0.63
+0.81%
After Hours: 78.39 -0.02 -0.03% 17:16 05/07 EDT
OPEN
78.01
PREV CLOSE
77.78
HIGH
78.66
LOW
77.89
VOLUME
11.67M
TURNOVER
--
52 WEEK HIGH
87.80
52 WEEK LOW
71.72
MARKET CAP
198.48B
P/E (TTM)
28.35
1D
5D
1M
3M
1Y
5Y
Top Research Reports for JPMorgan, Home Depot & Merck
Top Research Reports for JPMorgan, Home Depot & Merck
Zacks · 1h ago
BRIEF-Merck Says Declared Special Dividend For Organon Spinoff
reuters.com · 2h ago
Merck Declares Record Date and Dividend for the Organon & Co. Spinoff
Business Wire · 3h ago
Merk Declares Organon Will Begin Trade On NYSE On June 3 Under Symbol 'OGN'
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co.
Benzinga · 4h ago
Merck to Spin Off Organon Women's Health Unit to Shareholders on June 2
MT Newswires · 6h ago
Moderna (MRNA) Beats on Q1 Earnings, Ups Vaccine Sales View
Zacks.com · 6h ago
Corcept's (CORT) Q1 Earnings Miss Estimates, Revenues Fall Y/Y
Zacks.com · 7h ago
Nike, Amgen Inc. share gains lead Dow's nearly 100-point climb
marketwatch.com · 7h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRK. Analyze the recent business situations of Merck & Co through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 24 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRK stock price target is 94.02 with a high estimate of 107.00 and a low estimate of 77.00.
EPS
Institutional Holdings
Institutions: 3.29K
Institutional Holdings: 1.99B
% Owned: 78.66%
Shares Outstanding: 2.53B
TypeInstitutionsShares
Increased
1.19K
71.97M
New
277
7.95M
Decreased
888
83.69M
Sold Out
112
5.19M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.86%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Chief Executive Officer/Director
Kenneth Frazier
President
Robert Davis
Chief Financial Officer/Executive Vice President
Caroline Litchfield
Corporate Executive
Franklin Clyburn
Corporate Executive
Dean Li
Chief Human Resource Officer/Executive Vice President
Steven Mizell
Executive Vice President/General Counsel/Secretary
Jennifer Zachary
Executive Vice President
Frank Clyburn
Executive Vice President
Sanat Chattopadhyay
Executive Vice President
Richard DeLuca
Executive Vice President
Julie Gerberding
Senior Vice President - Finance/Controller
Rita Karachun
Senior Vice President/Chief Compliance Officer
Michael Fleming
Lead Director/Independent Director
Leslie Brun
Independent Director
Thomas Cech
Independent Director
Mary Coe
Independent Director
Pamela Craig
Independent Director
Thomas Glocer
Independent Director
Risa Lavizzo-Mourey
Independent Director
Stephen Mayo
Independent Director
Paul Rothman
Independent Director
Patricia Russo
Independent Director
Christine Seidman
Independent Director
Inge Thulin
Independent Director
Kathy Warden
Independent Director
Peter Wendell
Declaration Date
Dividend Per Share
Ex-Div Date
01/26/2021
Dividend USD 0.65
03/12/2021
11/17/2020
Dividend USD 0.65
12/14/2020
07/28/2020
Dividend USD 0.61
09/14/2020
05/26/2020
Dividend USD 0.61
06/12/2020
01/28/2020
Dividend USD 0.61
03/13/2020
11/19/2019
Dividend USD 0.61
12/13/2019
07/23/2019
Dividend USD 0.55
09/13/2019
05/28/2019
Dividend USD 0.55
06/14/2019
01/29/2019
Dividend USD 0.55
03/14/2019
10/25/2018
Dividend USD 0.55
12/14/2018
07/24/2018
Dividend USD 0.48
09/14/2018
05/22/2018
Dividend USD 0.48
06/14/2018
01/23/2018
Dividend USD 0.48
03/14/2018
11/28/2017
Dividend USD 0.48
12/14/2017
07/26/2017
Dividend USD 0.47
09/14/2017
05/23/2017
Dividend USD 0.47
06/13/2017
03/01/2017
Dividend USD 0.47
03/13/2017
11/22/2016
Dividend USD 0.47
12/13/2016
07/26/2016
Dividend USD 0.46
09/13/2016
05/24/2016
Dividend USD 0.46
06/13/2016
02/23/2016
Dividend USD 0.46
03/11/2016
11/24/2015
Dividend USD 0.46
12/11/2015
07/22/2015
Dividend USD 0.45
09/11/2015
05/26/2015
Dividend USD 0.45
06/11/2015
02/24/2015
Dividend USD 0.45
03/12/2015
11/25/2014
Dividend USD 0.45
12/11/2014
07/23/2014
Dividend USD 0.44
09/11/2014
05/27/2014
Dividend USD 0.44
06/12/2014
02/25/2014
Dividend USD 0.44
03/13/2014
11/26/2013
Dividend USD 0.44
12/12/2013
07/25/2013
Dividend USD 0.43
09/12/2013
About MRK
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.

Webull offers kinds of Merck & Co., Inc. stock information, including NYSE:MRK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRK stock methods without spending real money on the virtual paper trading platform.